Upcoming CTX310 Data Could Test The Case For CRISPR Therapeutics Stock

• CRISPR Therapeutics reported that Phase 1b clinical data for CTX310, its in vivo ANGPTL3 gene editing therapy for severe hypertriglyceridemia and cardiovascular conditions, were selected for a late breaking oral session at the American Heart Association Scientific Sessions 2026. The company stated that slides will be posted on its website after the November 9 presentation.
• The late breaking slot for CTX310 at a major cardiology meeting highlights how CRISPR Therapeutics is expanding its gene editing platform beyond hematology into cardiometabolic disease. This development could influence how investors consider the breadth of its potential revenue mix and required R&D spending.
• This article will examine how CRISPR Therapeutics' investment narrative intersects with the upcoming CTX310 Phase 1b cardiometabolic data spotlight.

Scan beyond CRISPR Therapeutics and size up other cardiometabolic and healthcare gene editing stories with our hand picked 34 healthcare AI stocks that could be building similar momentum.

CRISPR Therapeutics Investment Narrative Recap

To own CRISPR Therapeutics, you need to believe it can turn today’s gene editing toolkit into a set of real, scalable medicines. That story leans on CASGEVY uptake and disciplined use of its roughly US$2.4b cash balance to push CTX310, CTX611 and zugo cel through expensive late stage work without overwhelming dilution.

The AHA late breaking slot for CTX310 adds visibility but does not change the near term pivot point, which still rests on CASGEVY execution and cash burn control. The biggest risk stays the same. Ongoing losses and potential funding from higher risk borrowing or future equity could pressure existing holders.

Among recent developments, earlier CTX310 Phase 1a data already showed ANGPTL3 knockdown in the liver and reductions in LDL and triglycerides for at least a year. The new Phase 1b spotlight sits directly on that same program and puts a brighter operational focus on whether CRISPR Therapeutics can scale a cardiometabolic franchise beyond its hematology roots.

If CTX310 moves cleanly into later stage testing, it deepens the pipeline alongside CTX611 in total knee arthroplasty and zugo cel in autoimmune disease. That would give investors multiple shots on goal across cardiometabolic, anticoagulation and immune indications, while still keeping CASGEVY adoption and future funding decisions as the day to day execution test.

CRISPR Therapeutics' current analyst blueprint points to revenue of US$1.6b and earnings of US$128.2 million by 2029, anchored on a very large implied yearly revenue growth rate of about 394.2% and an earnings swing of roughly US$579 million from a loss of US$451.1 million today to the projected profit level.

Uncover why CRISPR Therapeutics' fair value indicates a 64% potential upside to its current price that may be short-lived.

Exploring Other Perspectives

One alternate angle on CRISPR Therapeutics is pure CTX310 optimism. The most bullish analysts were already modeling revenue of about US$5.6b and earnings near US$1.0b by 2029, assuming cardiometabolic programs really scale. You can read the AHA late breaker as a fresh test of that optimism, which may pull forecasts in very different directions.

Explore 3 other CRISPR Therapeutics fair value estimates, including one that suggests as much as 304% upside from the current price!

The Verdict Is Yours

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

• A great starting point for your CRISPR Therapeutics research is our analysis highlighting 2 key rewards that could impact your investment decision.
• See our latest analysis for CRISPR Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate CRISPR Therapeutics' overall financial health at a glance.

Looking For More Ideas Beyond CRISPR Therapeutics?

Once you have a view on CRISPR Therapeutics, it can help to line it up against a wider watchlist built around clear traits like value, resilience or income. The Simply Wall St Screener lets you quickly filter for other companies that fit the type of risk and return profile you want to research next.

• For investors who want quality at a marked down price, scan a curated 28 high quality undervalued stocks that match strong fundamentals with more modest expectations.
• If capital preservation sits near the top of your priorities, filter the market for a 31 resilient stocks with low risk scores that score well on financial strength and business stability.
• Income focused readers can zero in on a 8 dividend fortresses that combine higher yields with balance sheets you can scrutinize in detail before committing fresh capital.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com